(Q34727697)

4 August 2017

1 reference

title

Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue (English)

1 reference

4 August 2017

1 reference

Francesca Cainelli

2

0 references

Sandro Vento

object named as

Sandro Vento

series ordinal

1

0 references

author name string

Maria Serena Longhi

series ordinal

3

1 reference

4 August 2017

1 June 2002

1 reference

Lancet Oncology Commission

4 August 2017

1 reference

4 August 2017

3

1 reference

4 August 2017

6

1 reference

4 August 2017

333-340

1 reference

Massive hepatic necrosis after cyclophosphamide

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Bone-marrow transplantation (second of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Letter: Subacute and chronic active hepatitis after withdrawal of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Primary hepatocellular carcinoma with hepatitis B antigenemia: effects of chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Reactivation of hepatitis b after transplantation operations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Recurrence of hepatitis B after single lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatitis B: Evolving Epidemiology and Implications for Control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Treatment of HBV reactivation after withdrawal of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatitis B virus core antigen (HBc Ag) accumulation in an HBV nonproducer clone of HepG2-transfected cells is associated with cytopathic effect

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatitis B virus DNA contains a glucocorticoid-responsive element

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Non-Hodgkin's lymphoma and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Hepatitis C virus infection and lymphoproliferative diseases: prospective study on 1,576 patients in France

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

HCV and HGV in B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Interferon and cyclosporin A in the treatment of fulminant viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900773-8

7 January 2021

10.1016/S1470-2045(02)00773-8

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12107020